GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Other Gross PPE

I-MAB (IMAB) Other Gross PPE : $18.83 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Other Gross PPE?

I-MAB's Other Gross PPE for the quarter that ended in Dec. 2023 was $18.83 Mil.

I-MAB's quarterly Other Gross PPE declined from Dec. 2022 ($22.04 Mil) to Jun. 2023 ($14.31 Mil) but then increased from Jun. 2023 ($14.31 Mil) to Dec. 2023 ($18.83 Mil).

I-MAB's annual Other Gross PPE declined from Dec. 2021 ($26.38 Mil) to Dec. 2022 ($22.04 Mil) and declined from Dec. 2022 ($22.04 Mil) to Dec. 2023 ($18.83 Mil).

I-MAB Other Gross PPE Historical Data

The historical data trend for I-MAB's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Other Gross PPE Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial 7.49 9.12 26.38 22.04 18.83

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.38 28.03 22.04 14.31 18.83

I-MAB Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

I-MAB (IMAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Other Gross PPE
Comparable Companies
PLX GLSI CDXS CYT SEER PROK MLEC AADI ABSI GOSS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0VY:Germany
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
Website
https://www.i-mabbiopharma.com
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.